AI Portfolio Summary
In 2025 Q4, Vivo Capital, LLC maintained a portfolio of 54 distinct positions. The most significant new addition to the portfolio was Alto Neuroscience In, which now represents 1.19% of the total fund value. They heavily accumulated shares in Praxis Precision Med, increasing their position by 65.4%. Conversely, Vivo Capital, LLC completely exited their position in Verona Pharma PLC.
Total Positions
54
Quarter
2025 Q4
Top Holding
TERN (14.0%)
Top 10 Concentration
60.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 54
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TERN
Terns Pharmaceu...
|
Healthcare | 13.96% | 4.17% |
#1
3
Prev: #4
|
5.7 | -1,548,818 | -22.5% |
P
S
|
5,346,928 | $216,015,891 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
Cidara Therapeu...
|
Healthcare | 13.66% | 10.11% |
#2
1
Prev: #3
|
5.5 | -354,755 | -27.1% |
P
S
|
956,670 | $211,318,836 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
Praxis Precisio...
|
Healthcare | 6.27% | 0.85% |
#3
29
Prev: #32
|
4.7 | 130,000 | 65.4% |
P
S
|
328,895 | $96,938,512 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
Cogent Bioscien...
|
Healthcare | 5.51% | 3.22% |
#4
3
Prev: #7
|
2.2 | -390,144 | -14.0% |
P
S
|
2,398,993 | $85,212,231 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
Trevi Therapeut...
|
Healthcare | 4.12% | 3.75% |
#5
Prev: #5
|
1.6 | no change | no change |
P
S
|
5,094,668 | $63,785,243 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVDL
Avadel Pharmace...
|
Healthcare | 3.74% | 3.30% |
#6
Prev: #6
|
1.5 | no change | no change |
P
S
|
2,684,109 | $57,842,549 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPX
Compass Therape...
|
Healthcare | 3.31% | 2.69% |
#7
4
Prev: #11
|
1.3 | no change | no change |
P
S
|
9,545,466 | $51,259,152 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 3.31% | 2.66% |
#8
4
Prev: #12
|
1.3 | no change | no change |
P
S
|
2,614,960 | $51,148,618 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
Abivax SA - ADR
|
Healthcare | 3.13% | 2.45% |
#9
4
Prev: #13
|
1.3 | no change | no change |
P
S
|
359,305 | $48,454,076 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DBVT
DBV Technologie...
|
Healthcare | 3.05% | 0.85% |
#10
21
Prev: #31
|
3.5 | 1,407,120 | 133.4% |
P
S
|
2,461,626 | $47,189,370 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SABS
SAB Biotherapeu...
|
Healthcare | 2.76% | 1.85% |
#11
7
Prev: #18
|
1.1 | no change | no change |
P
S
|
11,420,000 | $42,710,800 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
Soleno Therapeu...
|
Healthcare | 2.68% | 12.39% |
#12
11
Prev: #1
|
1.3 | -1,383,294 | -60.7% |
P
S
|
894,909 | $41,434,287 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DRUG
Bright Minds Bi...
|
Healthcare | 2.53% | 2.45% |
#13
1
Prev: #14
|
1.0 | no change | no change |
P
S
|
501,617 | $39,146,191 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVA
Sinovac Biotech...
|
Unknown | 2.47% | 3.07% |
#14
6
Prev: #8
|
1.0 | no change | no change |
P
S
|
5,903,000 | $38,192,410 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GERN
Geron Corp
|
Healthcare | 2.32% | 3.00% |
#15
5
Prev: #10
|
0.9 | no change | no change |
P
S
|
27,225,292 | $35,937,385 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
Erasca Inc
|
Healthcare | 2.23% | 1.63% |
#16
5
Prev: #21
|
0.9 | no change | no change |
P
S
|
9,273,428 | $34,497,152 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZBIO
Zenas Biopharma...
|
Healthcare | 2.00% | 2.11% |
#17
1
Prev: #16
|
0.9 | -329,765 | -27.9% |
P
S
|
853,495 | $30,990,403 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
Viridian Therap...
|
Healthcare | 1.98% | 1.71% |
#18
1
Prev: #19
|
0.8 | no change | no change |
P
S
|
982,576 | $30,577,765 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACRS
Aclaris Therape...
|
Healthcare | 1.73% | 1.36% |
#19
4
Prev: #23
|
0.7 | no change | no change |
P
S
|
8,888,888 | $26,755,553 | 2016 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CAMP
CAMP4 Therapeut...
|
Healthcare | 1.68% | 0.95% |
#20
8
Prev: #28
|
2.7 | 325,000 | 8.3% |
P
S
|
4,246,568 | $26,031,462 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
Tango Therapeut...
|
Healthcare | 1.23% | 0.53% |
#21
17
Prev: #38
|
2.8 | 1,378,081 | 177.4% |
P
S
|
2,154,780 | $19,091,351 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANRO
Alto Neuroscien...
|
Healthcare | 1.19% | — |
#22
Prev: #—
|
2.5 | 1,035,551 | no change |
NEW
|
1,035,551 | $18,432,808 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LBRX
LB Pharmaceutic...
|
Healthcare | 1.15% | 1.02% |
#23
4
Prev: #27
|
0.5 | no change | no change |
P
S
|
800,000 | $17,808,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NERV
Minerva Neurosc...
|
Healthcare | 1.12% | — |
#24
Prev: #—
|
2.4 | 4,322,747 | no change |
NEW
|
4,322,747 | $17,377,443 | 2016 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORIC
Oric Pharmaceut...
|
Healthcare | 1.12% | 3.02% |
#25
16
Prev: #9
|
0.5 | -1,008,220 | -32.2% |
P
S
|
2,118,384 | $17,328,381 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRNA
Verona Pharma P...
|
Unknown | 0.00% | 11.97% |
Sold All 😨
(Was: #2) |
0.3 | -1,393,432 | -100.0% |
CLOSED
|
— | $— | 2017 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRML
Tourmaline Bio ...
|
Unknown | 0.00% | 2.28% |
Sold All 😨
(Was: #15) |
0.3 | -591,882 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
Akero Therapeut...
|
Healthcare | 0.00% | 1.66% |
Sold All 😨
(Was: #20) |
0.3 | -434,689 | -100.0% |
CLOSED
|
— | $— | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RZLT
Rezolute Inc
|
Healthcare | 0.00% | 1.60% |
Sold All 😨
(Was: #22) |
0.3 | -2,112,432 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATXS
Astria Therapeu...
|
Healthcare | 0.00% | 0.91% |
Sold All 😨
(Was: #29) |
0.3 | -1,552,685 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DCTH
Delcath Systems...
|
Healthcare | 0.00% | 0.49% |
Sold All 😨
(Was: #39) |
0.3 | -569,526 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ETNB
89Bio Inc
|
Unknown | 0.00% | 0.45% |
Sold All 😨
(Was: #41) |
0.3 | -376,804 | -100.0% |
CLOSED
|
— | $— | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 54 holdings